Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Completes Submission of CRC Test to FDA

NEW YORK (GenomeWeb News) – Epigenomics said today that it has completed the submission of its blood-based test for the detection of colorectal cancer for premarket approval by the US Food and Drug Administration.

The submission of the fourth and final module of its Epi proColon test last month included the results of a comparative, head-to-head study between this test and fecal immunochemical test screening, clinical validation study data, and other clinical study results that were generated during the test's development.

An Epigenomics test, based on the Septin9 protein, has been available as a CE-marked test kit in Europe and the Middle East since 2009, and, in 2011, it launched an improved version, the Epi proColon 2.0 CE.

"The non-inferiority of Septin9 to FIT demonstrated by the results of the head-to-head comparative study that were announced in Dec. 2012 was a very important milestone for us," Epigenomics' Acting CEO and CFO Thomas Taapken said in a statement.

"We continue to believe that our test is as effective as other non-invasive tests currently used with the added convenience of being a blood test, which will help drive screening compliance and therefore save more lives," Taapken added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.